PRNewswire
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US
2022-11-29
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
2022-11-21
GenScript takes home Executive of the Year – Biotechnology at the SBR Management Excellence Awards 2022
2022-11-18
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
2022-11-08
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23